Company Overview
About Scribe Therapeutics
Scribe Therapeutics was co-founded by Jennifer Doudna — who shared the 2020 Nobel Prize in Chemistry for CRISPR-Cas9 invention — and develops the ELXR platform: a CasX-based epigenetic silencing system that reduces gene expression without making permanent DNA cuts. The company has raised $100 million in Series B financing with strategic partnerships with Sanofi and Eli Lilly. The lead program, STX-1150, targets PCSK9 for durable LDL-C reduction and is projected to receive an IND and enter human trials in mid-2026.
Business Model & Competitive Advantage
The epigenetic silencing approach is ELXR's primary clinical safety differentiator from CRISPR gene editing: rather than cutting and permanently altering DNA (which CRISPR-Cas9 does), ELXR uses CasX to recruit epigenetic machinery that methylates the target gene's promoter — silencing transcription without changing the genetic sequence. This approach is potentially reversible and avoids the permanent off-target editing risks that regulatory agencies scrutinize most carefully in gene editing clinical trials.
Competitive Landscape 2025–2026
PCSK9 inhibition is one of the most commercially validated mechanisms in cardiovascular medicine: Repatha (evolocumab) and Praluent (alirocumab) generate $2+ billion annually. A one-time epigenetic silencing that achieves equivalent LDL-C reduction without monthly injection could transform the $2+ billion injectable PCSK9 market into a one-time treatment.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Scribe Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Growth Stage
Scribe Therapeutics has achieved $100M in revenue, demonstrating strong product-market fit.
Frequently Asked Questions
Not So Random Others
a2z Radiology AI
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disea
Adept AI
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and exec
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Plenty
Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has r
Oura
Oura is the maker of the Oura Ring, a premium smart ring that tracks sleep, recovery, readiness, and health metrics through continuous biometric sensing. The company raised $900 million in Series E fi
Nira Energy
Nira Energy is a Denver-based renewable energy software company providing grid capacity mapping and interconnection analysis tools that help solar, battery storage, and data center developers identify
Compare Scribe Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Scribe Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Scribe Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Scribe Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →